Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- dor abdominal
- perda de peso
- linfadenopatia
Outros fatores diagnósticos
- 50-70 anos de idade
- sexo masculino
- tabagismo
- história familiar
- náuseas
- disfagia
- hemorragia digestiva baixa
Fatores de risco
- anemia perniciosa
- Helicobacter pylori
- compostos N-nitrosos
- dieta pobre em frutas e legumes
- dieta com alto teor de sal
- tabagismo
- história familiar
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- endoscopia digestiva alta com biópsia
- Hemograma completo
- perfil metabólico completo
Investigações a serem consideradas
- TC do tórax/abdome/pelve
- ultrassonografia endoscópica
- laparoscopia
- PET/TC
Algoritmo de tratamento
Colaboradores
Autores
Ahmed Abdelhakeem, MD
Fellow Physician
Division of Hematology and Oncology
Mayo Clinic - Mayo Clinic Comprehensive Cancer Center
Jacksonville
FL
Declarações
AA declares that he has no competing interests.
Mariela Blum Murphy, MD
Associate Professor
Department of GI Medical Oncology
University of Texas
MD Anderson Cancer Center
Houston
TX
Declarações
MBM declares that she has no competing interests.
Agradecimentos
Dr Ahmed Abdelhakeem and Dr Mariela Blum Murphy would like to gratefully acknowledge Dr Valerie Reed and Dr Prajnan Das, previous contributors to this topic.
Declarações
VR and PD declare that they have no competing interests.
Revisores
Theodore Hong, MD
Director
Gastrointestinal Radiation Oncology
Massachusetts General Hospital Cancer Center
Boston
MA
Declarações
TH declares that he has no competing interests.
Andreas Leodolter, MD
Head of Department
Department of Gastroenterology
Sana Klinikum
Remscheid
Germany
Declarações
AL declares that he has no competing interests.
Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer [internet publication].Texto completo
Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Oct;33(10):1005-20.Texto completo Resumo
Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010 May;11(5):439-49. Resumo
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Resumo
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.Texto completo Resumo
Bang YJ, Van CE, Feyereislova A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível aqui.
O uso deste conteúdo está sujeito ao nosso aviso legal